vs
UiPath, Inc.（PATH）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是UiPath, Inc.的1.9倍（$772.1M vs $411.1M），UiPath, Inc.净利率更高（48.4% vs 12.7%，领先35.6%），UiPath, Inc.同比增速更快（15.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $25.1M），过去两年Revvity的营收复合增速更高（9.0% vs 0.7%）
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PATH vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$411.1M
营收增速更快
PATH
高出10.1%
5.9%
净利率更高
PATH
高出35.6%
12.7%
自由现金流更多
RVTY
多$136.7M
$25.1M
两年增速更快
RVTY
近两年复合增速
0.7%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $411.1M | $772.1M |
| 净利润 | $198.8M | $98.4M |
| 毛利率 | 83.3% | — |
| 营业利润率 | 3.2% | 14.5% |
| 净利率 | 48.4% | 12.7% |
| 营收同比 | 15.9% | 5.9% |
| 净利润同比 | 1966.2% | 3.9% |
| 每股收益（稀释后） | $0.37 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PATHRVTY
| Q4 25 | $411.1M | $772.1M | ||
| Q3 25 | $361.7M | $698.9M | ||
| Q2 25 | $356.6M | $720.3M | ||
| Q1 25 | $423.6M | $664.8M | ||
| Q4 24 | $354.7M | $729.4M | ||
| Q3 24 | $316.3M | $684.0M | ||
| Q2 24 | $335.1M | $691.7M | ||
| Q1 24 | $405.3M | $649.9M |
净利润PATHRVTY
| Q4 25 | $198.8M | $98.4M | ||
| Q3 25 | $1.6M | $46.7M | ||
| Q2 25 | $-22.6M | $53.9M | ||
| Q1 25 | $51.8M | $42.2M | ||
| Q4 24 | $-10.7M | $94.6M | ||
| Q3 24 | $-86.1M | $94.4M | ||
| Q2 24 | $-28.7M | $55.4M | ||
| Q1 24 | $33.9M | $26.0M |
毛利率PATHRVTY
| Q4 25 | 83.3% | — | ||
| Q3 25 | 82.2% | 53.6% | ||
| Q2 25 | 82.1% | 54.5% | ||
| Q1 25 | 84.8% | 56.5% | ||
| Q4 24 | 82.0% | — | ||
| Q3 24 | 80.0% | 56.3% | ||
| Q2 24 | 83.5% | 55.7% | ||
| Q1 24 | 86.8% | 54.6% |
营业利润率PATHRVTY
| Q4 25 | 3.2% | 14.5% | ||
| Q3 25 | -5.6% | 11.7% | ||
| Q2 25 | -4.6% | 12.6% | ||
| Q1 25 | 7.9% | 10.9% | ||
| Q4 24 | -12.2% | 16.3% | ||
| Q3 24 | -32.7% | 14.3% | ||
| Q2 24 | -14.8% | 12.4% | ||
| Q1 24 | 3.7% | 6.8% |
净利率PATHRVTY
| Q4 25 | 48.4% | 12.7% | ||
| Q3 25 | 0.4% | 6.7% | ||
| Q2 25 | -6.3% | 7.5% | ||
| Q1 25 | 12.2% | 6.4% | ||
| Q4 24 | -3.0% | 13.0% | ||
| Q3 24 | -27.2% | 13.8% | ||
| Q2 24 | -8.6% | 8.0% | ||
| Q1 24 | 8.4% | 4.0% |
每股收益（稀释后）PATHRVTY
| Q4 25 | $0.37 | $0.86 | ||
| Q3 25 | $0.00 | $0.40 | ||
| Q2 25 | $-0.04 | $0.46 | ||
| Q1 25 | $0.09 | $0.35 | ||
| Q4 24 | $-0.02 | $0.77 | ||
| Q3 24 | $-0.15 | $0.77 | ||
| Q2 24 | $-0.05 | $0.45 | ||
| Q1 24 | $0.07 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.4B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $7.3B |
| 总资产 | $2.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PATHRVTY
| Q4 25 | $1.4B | $919.9M | ||
| Q3 25 | $1.4B | $931.4M | ||
| Q2 25 | $1.6B | $991.8M | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.2B | ||
| Q3 24 | $1.7B | $1.2B | ||
| Q2 24 | $1.9B | $2.0B | ||
| Q1 24 | $1.9B | $1.7B |
股东权益PATHRVTY
| Q4 25 | $1.9B | $7.3B | ||
| Q3 25 | $1.7B | $7.4B | ||
| Q2 25 | $1.7B | $7.6B | ||
| Q1 25 | $1.8B | $7.6B | ||
| Q4 24 | $1.7B | $7.7B | ||
| Q3 24 | $1.8B | $7.9B | ||
| Q2 24 | $2.0B | $7.9B | ||
| Q1 24 | $2.0B | $7.8B |
总资产PATHRVTY
| Q4 25 | $2.9B | $12.2B | ||
| Q3 25 | $2.6B | $12.1B | ||
| Q2 25 | $2.6B | $12.4B | ||
| Q1 25 | $2.9B | $12.4B | ||
| Q4 24 | $2.7B | $12.4B | ||
| Q3 24 | $2.7B | $12.8B | ||
| Q2 24 | $2.8B | $13.4B | ||
| Q1 24 | $3.0B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $25.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.1% | 21.0% |
| 资本支出强度资本支出/营收 | 0.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 0.14× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流PATHRVTY
| Q4 25 | $28.3M | $182.0M | ||
| Q3 25 | $41.6M | $138.5M | ||
| Q2 25 | $119.0M | $134.3M | ||
| Q1 25 | $146.1M | $128.2M | ||
| Q4 24 | $28.1M | $174.2M | ||
| Q3 24 | $46.4M | $147.9M | ||
| Q2 24 | $100.0M | $158.6M | ||
| Q1 24 | $145.6M | $147.6M |
自由现金流PATHRVTY
| Q4 25 | $25.1M | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | $106.2M | $115.5M | ||
| Q1 25 | $138.7M | $112.2M | ||
| Q4 24 | $23.2M | $149.8M | ||
| Q3 24 | $45.0M | $125.6M | ||
| Q2 24 | $98.8M | $136.6M | ||
| Q1 24 | $141.8M | $129.7M |
自由现金流率PATHRVTY
| Q4 25 | 6.1% | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | 29.8% | 16.0% | ||
| Q1 25 | 32.7% | 16.9% | ||
| Q4 24 | 6.5% | 20.5% | ||
| Q3 24 | 14.2% | 18.4% | ||
| Q2 24 | 29.5% | 19.7% | ||
| Q1 24 | 35.0% | 20.0% |
资本支出强度PATHRVTY
| Q4 25 | 0.8% | 2.6% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 3.6% | 2.6% | ||
| Q1 25 | 1.7% | 2.4% | ||
| Q4 24 | 1.4% | 3.4% | ||
| Q3 24 | 0.4% | 3.3% | ||
| Q2 24 | 0.4% | 3.2% | ||
| Q1 24 | 0.9% | 2.7% |
现金转化率PATHRVTY
| Q4 25 | 0.14× | 1.85× | ||
| Q3 25 | 26.25× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 2.82× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | 4.29× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
